Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis, Otsuka - LARVOL DELTA

FLEXible and extended dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy in mCRPC (FLEX-MRT): A randomized phase 2 trial in progress (ESMO 2025) - No abstract available

Clinical • P2 data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

PSMACare trial-in-progress: a phase 2 trial of [177Lu]Lu-PSMA-617 with or without ARPI in patients with PSMA-positive non-metastatic castration-resistant prostate cancer (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Meta-analysis of survival outcomes of lutetium-177 PSMA-617 and androgen receptor pathway inhibitors combination therapy versus monotherapy in metastatic castration-resistant prostate cancer (ESMO 2025) - No abstract available

Combination therapy • Metastases • Monotherapy • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear Cell Renal Cell Carcinoma: a Multicentre Single-Arm Phase II Trial (RENALUT) (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor

Prevalence, clonal dynamics and clinical impact of clonal hematopoiesis (CH) in patients (pts) receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Investigating access to 177LuPSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) in France: comparative analysis with cabazitaxel using national hospital data (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy and Safety of 177Lu-PSMA-617 (LuPSMA) in Elderly Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

LuRa: Efficacy and Tolerability of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Retreatment with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) patientspts treated under the French early access program. (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Circulating tumour cell (CTC) characteristics associated with survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) in a randomised trial of enzalutamide with or without [177Lu]Lu-PSMA-617 (ENZA-p; ANZUP 1901). (ESMO 2025) - No abstract available

Circulating tumor cells • Clinical • Metastases • Tumor cell • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): a randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) (ESMO 2025) - No abstract available

Biomarker • Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

LuPARP: Phase 1 trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore study (ESMO 2025) - No abstract available

Clinical • Oncology

Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France. (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

177Lu-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE) (ESMO 2025) - No abstract available

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Show 1439: What Men Need to Know to Overcome Prostate Cancer - "Dr. Armstrong describes some of the different types of radiation, which can be very effective when used together with androgen blocking medication. There are also immune therapies. One exciting new therapy, called Pluvicto uses radioligands that seek out and attach to PSMA. Because it can find prostate cancer cells wherever they are in the body, it is being considered for treating metastatic prostate cancer when ADT may no longer be working well."

Audio

Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. (PubMed, Eur Urol Oncol) - "Among men with mCRPC previously exposed to an ARPI, continuation of the ARPI with [177Lu]Lu-PSMA-617 did not improve PSA50 response rates or OS after adjusting for cohort imbalances in known prognostic factors. Further post hoc analyses using large clinical trial data are needed."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types. (PubMed, Diagn Interv Imaging) - "Those include leveraging positron emission tomography (PET) findings to optimize the second-line use of 177Lu-DOTATATE in patients with metastatic and progressive neuroendocrine tumors or the use of prostate-specific membrane antigen (PSMA) PET findings to select patients with metastatic castration-resistant prostate cancer for treatment with 177Lu-PSMA-617. Given the wide potential applicability of emerging theranostic agents, it will be incumbent upon the field to carefully design clinical trials that will lead to regulatory approvals that will, in turn, permit broad use across a number of cancer types. In our future clinical practices, we will evolve to leverage precision medicine to identify target expression and deliver appropriate theranostic agents that are not limited to a specific cell of origin or disease state."

Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • CA9 • CXCR4

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "Baseline PSMA-TTV is prognostic for overall survival and predictive for a beneficial effect on overall survival with the addition of [177Lu]Lu-PSMA-617 to enzalutamide as first-line treatment for high-risk metastatic castration-resistant prostate cancer. By contrast, PSMA SUVmean was not prognostic for PSA progression-free survival or overall survival when [177Lu]Lu-PSMA-617 was administered with enzalutamide."

Journal • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). (PubMed, Eur J Nucl Med Mol Imaging) - "The Bellmunt Risk Score effectively stratifies mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. Its straightforward design, based on readily accessible clinical parameters, ensures practicality and utility in real-world clinical settings."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CRP

Radionuclides Landscape in Prostate Cancer Theranostics. (PubMed, Int J Mol Sci) - "Regulatory bodies have approved various PSMA-targeted radiodiagnostic agents, such as [18F]DCFPyL (PYLARIFY®, Lantheus Holdings), [18F]rhPSMA-7.3 (POSLUMA®, Blue Earth Diagnostics), and [68Ga]Ga-PSMA-11 (LOCAMETZ®, Novartis/ILLUCCIX®, Telix Pharmaceuticals), as well as therapeutic agents like [177Lu]Lu-PSMA-617 (PLUVICTO®, 15 Novartis)...Three clinically wise used radionuclides 177Lu, 225Ac, 223Ra are shown along with their characteristics. This review aims to elucidate the molecular mechanisms underpinning PSMA, explore the clinical applications of PSMA-targeted radiotheranostics, and critically examine the diverse challenges these therapies encounter in the treatment of prostate cancer."

Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

Influence of bone marrow segmentation approach on absorbed dose estimates in a single time point protocol for 177Lu-PSMA-617 (EANM 2025) - No abstract available

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of premedication on the frequency and intensity of Fatigue and Nausea in [¹⁷⁷Lu]Lu-PSMA-617 therapy: A Multicenter Analysis (EANM 2025) - No abstract available

Clinical • Fatigue

Non-Invasive Management of an Asymptomatic Lu-177-PSMA-617 Extravasation: A Case Report with Scintigraphic and Dosimetric Evaluation (EANM 2025) - No abstract available

Case report • Clinical • Non-invasive

Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy (EANM 2025) - No abstract available

Clinical • Oncology